Oliver Sexton
Investment Director @ UK Innovation & Science Seed Fund
London, United Kingdom
Oliver Sexton is a seed investor at UK Innovation & Science Seed Fund in London focused on Biotechnology and Health Care. Oliver is Head of Life Sciences at Future Planet Capital and manages investments from the UK Innovation and Science Seed Fund. He has invested in HC, ag tech, clean tech and AI businesses and sits on the board on a number of biotech companies. Prior to joining FPC, Oliver managed commercialisation of early stage HC technologies at ImperialInnovations/Touchstone and has previously managed licensing at Ark Therapeutics as well as various HC consultancy roles. He also manged a team of buy side analysts at Instinet. Oliver has an MSc from the University of Bristol and his PhD research was at the University of Nottingham.
- Total investments:
- 17
- Last investment:
- Lead investor:
- 29%
Last updated:
For AI agents: llms.txt
Industries Oliver Sexton invests in
Stages Oliver Sexton invests in
Countries Oliver Sexton invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 11 (65%)
- Health Care 4 (24%)
- Medical 3 (18%)
- AgTech 2 (12%)
- Life Science 2 (12%)
Stage
- Seed 8 (47%)
- Pre-Seed 3 (18%)
- Series A 2 (12%)
- Venture - Series Unknown 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Revolver Therapeutics develops peptide therapeutics that target transcription factors to create new routes to cancer treatment. The company uses a proprietary peptide discovery and screening platform, including its Transcription Block Survival technology, to identify functional peptide inhibitors in live cell systems. This platform enables rapidscreening of large peptide libraries and enrichment of molecules that functionally block or modulate transcription factor activity. Revolver Therapeutics focuses on translating its peptide-based transcription factor screening technology into therapeutic candidates for oncology. Its work is based on research spun out from the University of Bath and is aimed at generating next-generation peptide drugs for difficult-to-treat cancers. | $764K / Pre-Seed / Jul 03, 2026 | ||
| QuberTech develops biotechnology solutions to create an alternative natural rubber supply chain. The company engineers dandelion crops using precision breeding and gene editing to increase latex production in their roots to commercially viable levels. It integrates these crop innovations with soil-free, controlled-environment aeroponic farmingsystems designed for industrial rubber production. QuberTech focuses on controlled indoor cultivation to reduce exposure to climate and disease risks associated with traditional plantations. Its technology targets early applications in sectors that use high-specification natural rubber, including medical products, footwear, and fashion. The company also participates in collaborative research and development programmes such as the QuBOOSTR consortium to advance its platform toward commercial-scale facilities. | $4.6M / Seed / May 20, 2026 | ||
| Resurrect Bio is a plant biotechnology company that will improve the immune systems of crop species to revolutionize the agricultural industry. | $10.3M / Series A / Feb 17, 2026 | ||
| Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection. | $14M / Series A / Sep 11, 2024 | ||
| MitoRx Therapeutics is a biotechnology company developing novel therapeutics that reverse mitochondrial dysfunction. | $5M / Seed / Dec 13, 2023 | ||
| twig bio operates as a bioengineering startup. twig bio using AI and robotics to find sustainable replacements for harmful ingredients. | $3.7M / Pre-Seed / Sep 10, 2023 | ||
| Resurrect Bio is a plant biotechnology company that will improve the immune systems of crop species to revolutionize the agricultural industry. | $2M / Seed / May 16, 2023 | ||
| Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection. | $4.9M / Seed / Mar 27, 2023 | ||
| MicrofluidX is tackling the problems of process control, scalability, and cost associated with cell bioprocessing, in particular for autologous cell and gene therapy. | $4.3M / Seed / Dec 08, 2022 | ||
| MFX is a platform designed to accelerate the development and manufacturing of cell and gene therapies. | $4M / Seed / Dec 08, 2022 | ||
| See all 17 investments → | |||
Co-Investors
The UK Innovation & Science Seed Fund is backed by the Department for Business, Energy and Industrial Strategy and the Fund’s partners are 9 publicly funded research bodies, including STFC, BBSRC, NERC and Dstl. The Fund is independently managed by venture capital specialist Midven. They help build companies from great science developed in laboratories, science and technology campuses and synthetic biology. They hold investments in some of the UK’s most innovative companies, in areas as diverse as novel antibiotics, research into Alzheimer’s disease, “green” chemicals and airport security.
UK Innovation & Science Seed Fund Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alexander Leigh
Investment Director
|
|||
Andrew Muir
Investment Director & Fund Principal
|
|||
Mark White
Director
|
|||
|
Oliver Sexton
Investment Director
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Oliver Sexton invest in?
Oliver Sexton invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Pre-Seed stage. Most of the 17 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Oliver Sexton?
Public channels for Oliver Sexton include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Oliver Sexton last invest?
The most recent investment recorded for Oliver Sexton closed in Jul 2026. Shizune tracks 17 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
